ETF盘中资讯｜“AI制药第一股”拿下470亿大单！晶泰控股高开15%，创新药“新势力”港股通创新药ETF（520880）续涨逾1%

Core Viewpoint - The Hong Kong stock market opened slightly lower on August 6, with innovative drugs continuing to be active, particularly the high-profile Hong Kong Stock Connect innovative drug ETF (520880), which rose by 1.37% in early trading, aiming for a third consecutive daily gain [1]. Group 1: Company Developments - On August 5, Crystal Tech Holdings announced a pipeline collaboration agreement with DoveTree, with a total order scale of approximately HKD 470 billion (USD 59.9 billion), marking one of the largest business development transactions in China's AI pharmaceutical sector by 2025 [2][3]. - Crystal Tech Holdings has received an initial payment of USD 51 million under the final agreement and is entitled to further payments of USD 49 million (to be paid within 180 days), as well as potential milestone payments of up to USD 5.89 billion based on regulatory and commercial achievements, along with royalties based on annual net sales [3]. Group 2: Industry Trends - The domestic innovative drug sector is entering a period of technological breakthroughs, with the National Medical Products Administration reporting that 43 innovative drugs were approved in the first half of the year, a year-on-year increase of 59%, nearing the total of 48 for the entire year of 2024 [3]. - According to China International Capital Corporation, the long-term development trend of the innovative drug industry is promising, supported by domestic engineer advantages, abundant clinical resources, and favorable policies [3]. - The innovative drug sector is expected to benefit from policy reforms in payment systems, enhancing the profitability of innovative drug companies, with many stocks in the sector showing strength as they enter the 2.0 era [3]. Group 3: Market Performance - The Hong Kong Stock Connect innovative drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which focuses on the innovative drug industry chain, primarily consisting of innovative drug research and development companies [4]. - As of July 31, the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has risen by 101.58% year-to-date, significantly outperforming the Hang Seng Index (23.50%) and the Hang Seng Tech Index (22.05%) by 78.08 and 79.53 percentage points, respectively [6][7].